Summary
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Peripheral Arterial Disease (PAD) in 20 Major Markets
Peripheral Arterial disease (PAD) is an occlusion of the peripheral arteries and is widely viewed as a measure of an individual's global systemic atherosclerotic burden. Typically, it is defined as an ankle-brachial pressure index (APBI) ratio of <0.9. PAD can also be known as peripheral arterial occlusive disease, arteriosclerosis obliterans, lower extremity occlusive disease and peripheral vascular disease.
This report provides the current prevalent population for PAD across 20 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Mexico, Turkey, Greece, Netherlands, Saudi Arabia, Republic of Korea, China, Argentina, Canada, Australia and Sweden) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of PAD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for PAD include:
• Hypertension
• Family history of PAD
• Dyslipidaemia
• Obesity
• Diabetes
• Lower limb ischemia
• Myocardial infarction
• Coronary artery disease (CAD)
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global PAD’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of PAD and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on PAD’s prevalent population.
• Identify sub-populations within PAD which require treatment.
• Gain an understanding of the specific markets that have the largest number of PAD patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis &Clinical Course
• Key Co-morbid Conditions /Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Peripheral Arterial Disease
• Features of PAD
o Severity and Symptoms of PAD
o Profile of Symptoms in Symptomatic PAD Patients
o Cholesterol Levels in PAD Patients
o Conditions Associated with PAD
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• Fontaine Classification System for PAD
• Rutherford Classification System for PAD
• Society for Vascular Surgery WIfI for PAD classification
• Society for Vascular Surgery TASC II Classification for PAD
• Prevalence of PAD, total (000s)
• Prevalence of PAD, males (000s)
• Prevalence of PAD, females (000s)
• PAD patients by severity, total (000s)
• PAD patients by symptom status, total (000s)
• Small-vessel or large-vessel involvement in PAD patients, total (000s)
• Profile of IC type in Symptomatic PAD patients, total (000s)
• Grade of symptoms in symptomatic PAD patients, total (000s)
• 1-year outcome of patients with acute limb ischemia, total (000s)
• Total cholesterol in PAD patients, total (000s)
• Prevalence of hypertension in PAD patients, total (000s)
• Prevalence of diabetes in PAD patients, total (000s)
• Prevalence of CHF in PAD patients, total (000s)
• Prevalence of CAD in PAD patients, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of PAD by 5-yr age cohort, males (000s)
• USA Prevalence of PAD by 5-yr age cohort, females (000s)
• France Prevalence of PAD by 5-yr age cohort, males (000s)
• France Prevalence of PAD by 5-yr age cohort, females (000s)
• Germany Prevalence of PAD by 5-yr age cohort, males (000s)
• Germany Prevalence of PAD by 5-yr age cohort, females (000s)
• Italy Prevalence of PAD by 5-yr age cohort, males (000s)
• Italy Prevalence of PAD by 5-yr age cohort, females (000s)
• Spain Prevalence of PAD by 5-yr age cohort, males (000s)
• Spain Prevalence of PAD by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of PAD by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of PAD by 5-yr age cohort, females (000s)
• Brazil Prevalence of PAD by 5-yr age cohort, males (000s)
• Brazil Prevalence of PAD by 5-yr age cohort, females (000s)
• Japan Prevalence of PAD by 5-yr age cohort, males (000s)
• Japan Prevalence of PAD by 5-yr age cohort, females (000s)
• India Prevalence of PAD by 5-yr age cohort, males (000s)
• India Prevalence of PAD by 5-yr age cohort, females (000s)
• Mexico Prevalence of PAD by 5-yr age cohort, males (000s)
• Mexico Prevalence of PAD by 5-yr age cohort, females (000s)
• Turkey Prevalence of PAD by 5-yr age cohort, males (000s)
• Turkey Prevalence of PAD by 5-yr age cohort, females (000s)
• Sweden Prevalence of PAD by 5-yr age cohort, males (000s)
• Sweden Prevalence of PAD by 5-yr age cohort, females (000s)
• Canada Prevalence of PAD by 5-yr age cohort, males (000s)
• Canada Prevalence of PAD by 5-yr age cohort, females (000s)
• Australia Prevalence of PAD by 5-yr age cohort, males (000s)
• Australia Prevalence of PAD by 5-yr age cohort, females (000s)
• Greece Prevalence of PAD by 5-yr age cohort, males (000s)
• Greece Prevalence of PAD by 5-yr age cohort, females (000s)
• Saudi Arabia Prevalence of PAD by 5-yr age cohort, males (000s)
• Saudi Arabia Prevalence of PAD by 5-yr age cohort, females (000s)
• South Korea Prevalence of PAD by 5-yr age cohort, males (000s)
• South Korea Prevalence of PAD by 5-yr age cohort, females (000s)
• The Netherlands Prevalence of PAD by 5-yr age cohort, males (000s)
• The Netherlands Prevalence of PAD by 5-yr age cohort, females (000s)
• Argentina Prevalence of PAD by 5-yr age cohort, males (000s)
• Argentina Prevalence of PAD by 5-yr age cohort, females (000s)
• China Prevalence of PAD by 5-yr age cohort, males (000s)
• China Prevalence of PAD by 5-yr age cohort, females (000s)
